# Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/TARA/protara-therapeutics-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4
Ticker: TARA
Company: Protara Therapeutics
Source: Protara Therapeutics
Published: 2026-02-02 21:05 EST
Original Source URL: https://ir.protaratx.com
## Summary

NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options

## Article Body
NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options
## Recent Company News
- 2026-05-20 12:00 EST — [Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA](https://biopharmsignal.com/news/TARA/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-and-eha) — Source: Protara Therapeutics
- 2026-05-18 12:00 EST — [Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026](https://biopharmsignal.com/news/TARA/protara-therapeutics-to-host-virtual-investor-webinar-to-discuss-tara-002-for-lymphatic-malformations-on-tuesday-may-19-2026) — Source: Protara Therapeutics
- 2026-05-15 11:00 EST — [Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC](https://biopharmsignal.com/news/TARA/protara-therapeutics-announces-positive-updated-12-month-data-demonstrating-durable-responses-in-the-fully-enrolled-bcg-naive-cohort-of-the-ongoing-phase-2-advanced-2-trial-of-tara-002-in-nmibc) — Source: Protara Therapeutics
- 2026-05-13 12:00 EST — [Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update](https://biopharmsignal.com/news/TARA/protara-therapeutics-announces-first-quarter-2026-financial-results-and-provides-a-business-update) — Source: Protara Therapeutics
- 2026-04-27 20:05 EST — [Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting](https://biopharmsignal.com/news/TARA/protara-therapeutics-to-present-updated-interim-12-month-data-from-the-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-american-urological-association-annual-meeting) — Source: Protara Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)